darolutamide plus androgen deprivation therapy

DRUG2 trials

Sponsors

Pfizer, Bayer

Conditions

Metastatic Castration Sensitive Prostate Cancer (mCSPC)Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Unknown Phase

A Study to Learn About the Outcomes Between Study Medicines, Enzalutamide and Darolutamide Among Men With Metastatic Castration Sensitive Prostate Cancer (mCSPC)

Not yet recruitingNCT07779590

PfizerMetastatic Castration Sensitive Prostate Cancer (mCSPC)

Start: 2026-09-01End: 2026-11-15Target: 4700Updated: 2026-08-21

A Study of Darolutamide Plus Androgen Deprivation Therapy in Patients With Metastatic Hormone-sensitive Prostate Cancer in India

Not yet recruitingNCT07806591

BayerMetastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Start: 2026-10-05End: 2028-10-31Target: 50Updated: 2026-09-10